Phase 3 DREAMM-8 Trial Data Show Superior Efficacy of BPd vs PVd in Relapsed/Refractory Multiple Myeloma

by | Jun 4, 2024 | Myeloma News | 0 comments

Source: Pharmacy Times articles

The study showed that belantamab mafodotin plus pomalidomide and dexamethasone (BPd) significantly improved progression-free survival compared to pomalidomide plus bortezomib and dexamethasone (PVd).
Read More

Submit a Comment